Biotech China 2014

View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2011 Thrombin expression in prostate: a novel finding Cancer Invest. 2011 Jan; 29(1):62-7. PMID:21166500. DOI:10.3109/07357907.2010.535057
2. 2011 Novel Molecular Targets of Azadirachta indica Associated with Inhibition of Tumor Growth in Prostate Cancer AAPS J. 2011 May 11. [Epub ahead of print] PMID:21560017. DOI:10.1208/s12248-011-9279-4.
3. 2011 Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib Clin Adv Hematol Oncol. 2011 Apr; 9(4):335-8. PMID:21558995.
4. 2010 New developments in the medical management of prostate cancer Mayo Clin Proc. 2010 Jan; 85(1):77-86. PMID:20042563. PMCID:2800284. DOI:10.4065/mcp.2009.0442.
5. 2010 Multiple urinary bladder masses from metastatic prostate adenocarcinoma Rare Tumors. 2010; 2(4):186-188. DOI:10.4081/rt.2010e65.
6. 2010 Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomark. 2010; 7(2):101-8. PMID:21178268. DOI:10.3233/CBM-2010-0152.
7. 2010 Endocrine Manipulations CANCER: Principles and Practice of Oncology 2010. (Book chapter)
8. 2010 Hormonal Therapy in Prostate Cancer Encyclopedia of Cancer 3rd ed. 2010. (Book chapter)
9. 2009 Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study. Cancer Invest. 2009 May; 27(4):430-4. PMID:19219655. DOI:10.1080/07357900802527247.
10. 2008 Expression of tissue factor in prostate cancer correlates with malignant phenotype Appl Immunohistochem Mol Morphol. 2008 Jan; 16(1):1-6. PMID:18091328. DOI:10.1097/01.pai.0000213157.94804.fc.
11. 2006 Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark. 2006; 2(6):249-58. PMID:17264396.
12. 2006 Metastasectomy for isolated bilateral adrenal metastases in hormone-refractory prostate cancer. Clin Adv Hematol Oncol. 2006 Oct; 4(10):754-5; discussion 756-7. PMID:17099632.
13. 2006 Management of solitary palatal metastasis from renal cell carcinoma Nat Clin Pract Urol. 2006 Jul; 3(7):392-6; quiz following 396. PMID:16835627. DOI:10.1038/ncpuro0536
14. 2006 Evaluation of an adrenal mass in a patient with progressive prostate cancer reveals pheochromocytoma. Int J Urol. 2006 Jun; 13(6):798-800. PMID:16834663. DOI:10.1111/j.1442-2042.2006.01405.x.
15. 2006 Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21.
16. 2005 Stage specific expression of VEGF A and D in prostate cancer Clin Cancer Res. 2005; 11:1-10.
17. 2005 Thrombin and thrombin receptor expression in prostate cancer. Prostate. 2005 Oct 21
18. 2005 Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2, Interferon in Patients with Metastatic Renal Cell Carcinoma J Clin Oncol. 2005 Sep 1; 23(25):6267-8.
19. 2005 Orbital metastasis from prostate cancer: an atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage Clin Prostate Cancer. 2005 Sep; 4(2):134-7. PMID:16197616.
20. 2005 Ocular melanoma versus ocular metastasis: a diagnostic dilemma. Clin Adv Hematol Oncol. 2005 May; 3(5):425-7. PMID:16167017
21. 2004 COX-2: an inconsistent therapeutic target in prostate cancer Uro Oncology. 2004 Sept/Dec; 4(3/4):113-8.
22. 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 7; 351(15):1513-20
23. 2004 The academic hematology-oncology firm: a model for postgraduate cancer education J Cancer Educ. 2004 Spr; 19(1):45-9. PMID:15059755.
24. 2003 Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer Urology. 2003 Apr; 61(4):765-9. PMID:12670562.
25. 2003 Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management? J Clin Oncol. 2003 Jun 15; 21(12):2445. PMID:12805351.
26. 2003 Role of coagulation and fibrinolytic system in prostate cancer Semin Thromb Hemost. 2003 Jun; 29(3):301-8. PMID:12888934
27. 2003 Potential anticancer effects of statins: fact or fiction? Endothelium. 2003; 10(1):49-58. PMID:12699077
28. 2002 Endothelial dysfunction in antiangiogenesis-associated thrombosis. J Clin Oncol. 2002 Jul 1; 20(13):3042; author reply 3042-3. PMID:12089240.
29. 2002 Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer Blood Coagul Fibrinolysis. 2002 Jan; 13(1):1-5. PMID:11994561
30. 2000 Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice. South Med J. 2000 May; 93(5):469-71. PMID:10832943
31. 1999 Impact of nutrition on the age related declines in heamatopoiesis Chernoff R. Geriatric nutrition the health professional’s handbook. 2nd ed. Aspen: Jones & Bartlett Publishers; 1999. (Book chapter)

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.